Lamisil is a drug owned by Karo Healthcare Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 28, 2015. Details of Lamisil's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5681849 (Pediatric) | Pharmaceutical composition for topical applications |
Apr, 2015
(9 years ago) |
Expired
|
| US5681849 | Pharmaceutical composition for topical applications |
Oct, 2014
(10 years ago) |
Expired
|
|
US6005001 (Pediatric) | Pharmaceutical composition |
Nov, 2012
(12 years ago) |
Expired
|
|
US5856355 (Pediatric) | Pharmaceutical composition |
Nov, 2012
(12 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Lamisil is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lamisil's family patents as well as insights into ongoing legal events on those patents.
Lamisil's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lamisil's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 28, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lamisil Generics:
There are no approved generic versions for Lamisil as of now.
Alternative Brands for Lamisil
There are several other brand drugs using the same active ingredient (Terbinafine) as Lamisil. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Karo Hlthcare |
|
About Lamisil
Lamisil is a drug owned by Karo Healthcare Inc. Lamisil uses Terbinafine as an active ingredient. Lamisil was launched by Karo Hlthcare in 1998.
Approval Date:
Lamisil was approved by FDA for market use on 29 April, 1998.
Active Ingredient:
Lamisil uses Terbinafine as the active ingredient. Check out other Drugs and Companies using Terbinafine ingredient
Dosage:
Lamisil is available in gel form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1% | GEL | Discontinued | TOPICAL |